Spectrum Pharmaceuticals Highlights Three Abstracts of Clinical Data at the 2017 American Society of Clinical Oncology (ASCO)...
June 02 2017 - 7:00AM
Business Wire
Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology
company with fully integrated commercial and drug development
operations with a primary focus in Hematology and Oncology, today
announced presentations of clinical data for FOLOTYN® (pralatrexate
injection) and MARQIBO® (vinCRIStine sulfate LIPOSOME injection) to
be presented at the American Society of Clinical Oncology (ASCO)
Annual Meeting, being held in Chicago, Illinois, from June 2- 6,
2017.
For more information about the ASCO Annual Meeting and for a
complete list of abstracts, please refer to the conference website
at http://www.sppirx.com/LinkThrough/LinkThroughASCO.html
FOLOTYN(®) (pralatrexate injection) related abstract:
Monday June 5, 2017, 8:00 AM-11:30 AM
CDT
Abstract # Type
Title First Author
Location
7521
Poster Innovative approach to determine overall survival (OS)
benefit for orphan diseases using case match control analyses
(CMCA): The PROPEL experience of pralatrexate in patients with
relapsed/refractory (R/R) peripheral T-cell lymphoma (PTCL).
O’Connor Hall A
MARQIBO® (vinCRIStine
sulfate LIPOSOME injection) related abstracts:
Saturday June 3, 2017, 3:00 PM-6:00 PM
CDT
Abstract # Type Title First
Author Location 7506 Oral Radiotherapy to bulky disease
PET-negative after immunochemotherapy in elderly DLBCL patients:
Results of a planned interim analysis of the first 187 patients
with bulky disease treated in the OPTIMAL>60 study of the
DSHNHL. Pfreundschuh S100bc
Monday June 5, 2017, 8:00 AM-11:30 AM
CDT
Abstract # Type Title First
Author Location 7539 Poster Anti-infective prophylaxis
with aciclovir and cotrimoxazole to reduce the rate of infections
and therapy-associated deaths in elderly patients with DLBCL
undergoing R-CHOP immunochemotherapy. Murawski Hall A
About Spectrum Pharmaceuticals, Inc.
Spectrum Pharmaceuticals is a leading biotechnology company
focused on acquiring, developing, and commercializing drug
products, with a primary focus in Hematology and Oncology. Spectrum
currently markets six hematology/oncology drugs, and has an
advanced stage pipeline that has the potential to transform
the Company. Spectrum's strong track record for in-licensing and
acquiring differentiated drugs, and expertise in clinical
development have generated a robust, diversified, and growing
pipeline of product candidates in advanced-stage Phase 2 and Phase
3 studies. More information on Spectrum is available
at www.sppirx.com.
Forward-looking statement — This press release may contain
forward-looking statements regarding future events and the future
performance of Spectrum Pharmaceuticals that involve risks and
uncertainties that could cause actual results to differ materially.
These statements are based on management's current beliefs and
expectations. These statements include, but are not limited to,
statements that relate to Spectrum’s business and its future,
including certain company milestones, Spectrum's ability to
identify, acquire, develop and commercialize a broad and diverse
pipeline of late-stage clinical and commercial products, the timing
and results of FDA decisions, and any statements that relate to the
intent, belief, plans or expectations of Spectrum or its
management, or that are not a statement of historical fact. Risks
that could cause actual results to differ include the possibility
that Spectrum’s existing and new drug candidates may not prove safe
or effective, the possibility that our existing and new
applications to the FDA and other regulatory agencies may not
receive approval in a timely manner or at all, the possibility that
our existing and new drug candidates, if approved, may not be more
effective, safer or more cost efficient than competing drugs, the
possibility that our efforts to acquire or in-license and develop
additional drug candidates may fail, our dependence on third
parties for clinical trials, manufacturing, distribution and
quality control and other risks that are described in further
detail in the Company's reports filed with the Securities and
Exchange Commission. The Company does not plan to update any such
forward-looking statements and expressly disclaims any duty to
update the information contained in this press release except as
required by law.
SPECTRUM PHARMACEUTICALS, INC.®, FOLOTYN® and MARQIBO® are
registered trademarks of Spectrum Pharmaceuticals, Inc and its
affiliate. REDEFINING CANCER CARE™ and the Spectrum Pharmaceuticals
logos are trademarks owned by Spectrum Pharmaceuticals, Inc. Any
other trademarks are the property of their respective owners.
© 2017 Spectrum Pharmaceuticals, Inc. All Rights Reserved
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170602005138/en/
Spectrum Pharmaceuticals, Inc.Shiv KapoorVice President,
Strategic Planning & Investor
Relations702-835-6300InvestorRelations@sppirx.com
Spectrum Pharmaceuticals (NASDAQ:SPPI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Spectrum Pharmaceuticals (NASDAQ:SPPI)
Historical Stock Chart
From Sep 2023 to Sep 2024